Life experiences put their stamp on the next generation: New insights from epigenetics
A review from Biological Psychiatry
Philadelphia, PA, February 14, 2013 – The 18th century natural philosopher Jean-Baptiste Lamarck proposed that the necks of giraffes lengthened as a consequence of the cumulative effort, across generations, to reach leaves just out of their grasp. This view of evolution was largely abandoned with the advent of modern genetic theories to explain the transmission of most important traits and many medical illnesses across generations.
However, there has long been the impression that major life events, like psychological traumas, not only have effects on individuals who directly experience these events, but also have effects on their children. For example, cross-generational effects have been well-documented in the children of Nazi death camp survivors. Similar issues have been reported in the context of mood disorders and addiction. Until recently, these trans-generational effects were attributed to changes in the way that parents treated their children or the child’s reaction to learning about the parent’s history.
In the most recent issue of Biological Psychiatry, Swiss researchers from the University of Zurich and Swiss Federal Institute of Technology, led by Dr. Isabelle Mansuy, discuss how the emergence of the field of epigenetics has introduced a new component to this discussion – the trans-generational transmission of changes in the regulation of gene expression.
“The question of the inheritance of acquired traits has puzzled biologists and clinicians for decades. Although it has been consistently observed as early as in the 18th century, the time has now come that sufficiently strong and convincing evidence has accumulated to firmly accept it,” said Mansuy.
The genetic transmission of traits reflects alterations in genetic structure, i.e., the base pairs that form DNA. Epigenetics, on the other hand, involves cellular processes that do not alter the structure of DNA. Instead, epigenetic mechanisms, including the methylation of DNA or of specific residues on histone “supporter” proteins, influence the extent to which individual genes are converted into messenger RNA. These changes can occur in any cell of the body, but when they occur in the germ cells (sperm or eggs) the changes may be passed to the next generation.
The changes in DNA structure are random events that acquire functional significance in the context of Darwin’s “natural selection” process. In contrast, the epigenetic reactions to specific environments are designed to enable that organism to cope with that context. When these traits are passed to the next generation, it is as if the newborn arrives prepared for that specific environment. Problems arise when the epigenetic processes give rise to traits that are not adaptive for the offspring, such as heightened stress reactivity, or when the environment has changed.
“This is a remarkable story with far-reaching implications,” commented Dr. John Krystal, Editor of Biological Psychiatry. “There is a suspicion that epigenetic processes may be reversed more easily than genetic traits, exemplified by the development of HDAC inhibitors. This is a rapidly evolving research area that has captured a great deal of attention.”
The article is “Transgenerational Epigenetic Effects on Brain Functions” by Johannes Bohacek, Katharina Gapp, Bechara J. Saab, and Isabelle M. Mansuy (doi: 10.1016/j.biopsych.2012.08.019). The article appears in Biological Psychiatry, Volume 73, Issue 4 (February 15, 2013), published by Elsevier.
Notes for Editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Isabelle Mansuy at +41 44 635 3360 or firstname.lastname@example.org.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 129 Psychiatry titles and 16th out of 243 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2011 Impact Factor score for Biological Psychiatry is 8.283.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).